18+ · Research Use Only · Not for Human Consumption
Tirzepatide · Phase 3 · Completed
SURMOUNT-2
In SURMOUNT-2, a phase 3 trial of tirzepatide in adults (18 or older) with BMI of 27 kg/m2 or higher and type 2 diabetes with HbA1c 7-10% (53-86 mmol/mol), in seven countries (n=938), mean body weight fell 12.8% on 10 mg and 14.7% on 15 mg over 72 weeks, against 3.2% on placebo (treatment-regimen estimand; Garvey WT et al. Lancet 2023 (SURMOUNT-2)).
Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked.
Results
Side effects reported
SURMOUNT-2: The abstract reports that few adverse events led to discontinuation (under 5%) without per-arm figures.
Design
Trial design and sources
- Compound
- Tirzepatide
- Phase
- 3
- Population
- Adults (18 or older) with BMI of 27 kg/m2 or higher and type 2 diabetes with HbA1c 7-10% (53-86 mmol/mol), in seven countries
- Participants randomised
- 938
- Duration
- 72 weeks
- Primary endpoint
- Coprimary: percent change in bodyweight from baseline and bodyweight reduction of 5% or higher (week 72)
- Estimand
- treatment-regimen
- Read out
- 26 June 2023
The abstract reports that few adverse events led to discontinuation (under 5%) without per-arm figures.
Questions
SURMOUNT-2, answered
What did SURMOUNT-2 find?
In SURMOUNT-2, a phase 3 trial of tirzepatide in adults (18 or older) with BMI of 27 kg/m2 or higher and type 2 diabetes with HbA1c 7-10% (53-86 mmol/mol), in seven countries (n=938), mean body weight fell 12.8% on 10 mg and 14.7% on 15 mg over 72 weeks, against 3.2% on placebo (treatment-regimen estimand; Garvey WT et al. Lancet 2023 (SURMOUNT-2)).
What side effects were reported in SURMOUNT-2?
SURMOUNT-2: The abstract reports that few adverse events led to discontinuation (under 5%) without per-arm figures.
Related